Tenderwize
Wróć do wyszukiwania

Pharmaceutical discount contracts from 01.05.2025 for various active substances within the framework of an Open-House procedure

AOK NordWest - Die Gesundheitskasse·Dortmund, Germany·Deadline Feb 22, 2027 · 180 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Arzneimittel-Rabattverträge ab 01.05.2025 zu diversen Wirkstoffen im Rahmen eines Open-House-Verfahrens

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

20 / 100

Czynniki ryzyka

The buyer may award exclusive discount contracts during the term, causing the Open-House contracts to be suspended. The...

No contract value or volume is published; potential revenue is unknown.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Supply of pharmaceutical products for the listed active substances
  • Conclusion of discount agreements under §130a Abs. 8 SGB V
Pokaż pełne podsumowanie

Open-House procedure for pharmaceutical discount contracts (Rabattverträge) under §130a Abs. 8 SGB V for six active substances, offered by AOK NordWest. The procedure is not a public procurement under EU law; any eligible pharmaceutical entrepreneur may join at any time. Contracts run for max 24 months starting 01.05.2025. No estimated value disclosed. Non-exclusive, but the buyer may later award exclusive contracts that suspend these agreements.

Ryzyka

The buyer may award exclusive discount contracts during the term, causing the Open-House contracts to be suspended. The...

No contract value or volume is published; potential revenue is unknown.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in §4 Abs. 18 AMG for the offered medicinal products

Eligibility

  • Eligibility must persist for the entire contract duration

Administrative

  • Uniform contract terms apply; no individual negotiations

Zamawiający

Lokalizacja

Dortmund, DEU

Identyfikator

DE124159739

Działalność

Health

Części (1)

LOT-0001

Pharmaceutical discount contracts from 01.05.2025 for various active substances within the framework of an Open-House procedure

Uniform terms for all interested pharmaceutical entrepreneurs covering active substances: Aclidiniumbromide & Formoterol (R03AL05), Carglumic acid (A16AA05), Dabigatran (B01AE07), Mepolizumab (R03DX09), Opipramol (N06AA05), Pegfilgrastim (L03AA13). Earliest start 01.05.2025, duration max 24 months.

SuppliesEU fundedElectronic submission

Lokalizacja

Hagen, Germany

Czas trwania

Apr 2025 - Apr 2027

Kategoria

Pharmaceutical products

Termin

Deadline Feb 22, 2027

Szczegóły zamówienia

Data publikacji
03 Mar 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
141923-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3